

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
				Application Number	10/809,631
				Filing Date	March 24, 2004
				First Named Inventor	Nathan Andrew Shapira
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	UF-368XC1
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
<i>SW</i>	U1	US 2002/103206	A1	Berendsen	08-01-2002
	U2				
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				
	U10				
	U11				
	U12				
	U13				
	U14				


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴ (if known)		
<i>SW</i>	F1		NL 1014289	C	Waldinger et al.
<i>SW</i>	F2		WO 03/011340	A1	Wohlrab Johannes
<i>SW</i>	F3		WO 99/52517	A2	Sigma Tau Ind. Farmaceutici.
<i>SW</i>	F4		WO 00/23057	A2	Janssen Pharmaceutica N.V.
	F5				
	F6				
	F7				

Examiner Signature	<i>S. W. S.</i>	Date Considered	9/21/07
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SEP 27 2004

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

Complete if Known

Application Number	10/809,631
Filing Date	March 24, 2004
First Named Inventor	Nathan Andrew Shapira
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	UF-368XC1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SW	R1	KRISTIANSEN, KURT <i>et al.</i> , "Molecular modeling of serotonin, ketanserin, ritanserin and their 5-HT receptor interactions," <i>European Journal of Pharmacology</i> (1996), 306:195-210.	
	R2	LE WITT, PETER, "Hyperhidrosis and hypothermia responsive to oxybutynin," <i>Neurology</i> (1988), 38:506-507.	
	R3	LI, JAMES P. <i>et al.</i> , "Roles of 5-HT receptors in the release and action of secretion on pancreatic secretion in rats," <i>Am. J. Physiol.</i> (2001), 280:G595-G602.	
	R4	MARCY, R. <i>et al.</i> , "Anhidrotic Activity of Anti Cholinergics in Mice use of Different Routes of Administration," <i>Annales de Dermatologie et de Venereologie</i> (1977), 104:500-501.	
	R5	PASQUINI, M. <i>et al.</i> , "Mirtazapine for hyperhidrosis," <i>Psychosomatics</i> , United States (2003), 44(5):442-443.	
	R6	POMIER-LAYRARGUES, G. <i>et al.</i> , "Combined Treatment of Portal Hypertension with Ritanserin and Propranolol in Conscious and Unrestrained Cirrhotic Rats," <i>Hepatology</i> (1992), 15:878-882.	
	R7	SAADIA, DANIELA <i>et al.</i> , "Botulinum toxin type A in primary palmar hyperhidrosis: Randomized, single-blind, two-dose study," <i>Neurology</i> (2001), 57:2095-2099.	
	R8	SCHMIDT, ANNE W. <i>et al.</i> , "Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile," <i>European Journal of Pharmacology</i> (2001), 425:197-201.	
	R9	SEVILLE, R. H. <i>et al.</i> , "Treatment of Hyperhidrosis with Topical Propantheline -- a New Technique," <i>British Journal of Dermatology</i> (1972), 86:441.	
SW	R10	WILLIAMS, F. M. <i>et al.</i> , "Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers," <i>British Journal of Clinical Pharmacology</i> (1986), 22:301-308.	
	R11		
	R12		
	R13		

Examiner Signature

S. Ward

Date Considered

8/21/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(use as many sheets as necessary)				Filing Date	
Sheet	1	of	2	First Named Inventor	Shapira
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	UF-368X

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
<i>S, W</i>	U1	US 4,062,848		van der Burg	12-13-1977
	U2	US 4,342,762		Budai et al.	08-03-1982
	U3	US 5,730,964		Waldstreicher	03-24-1998
	U4	US 6,420,541	B1	Behan et al.	07-16-2002
	U5	US 6,433,003	B1	Bobrove et al.	08-13-2002
<i>S, W</i>	U6	US 6,455,567	B1	Monkhouse et al.	09-24-2002
	U7				
	U8				
	U9				
	U10				
	U11				
	U12				
	U13				
	U14				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
<i>S, W</i>	F1	WO	98/17230	A2	Egis Gyogyszergyar RT	04-30-1998
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	<i>S, W</i>	Date Considered	<i>9/14/07</i>
--------------------	-------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	
Filing Date	
First Named Inventor	Shapira
Group Art Unit	
Examiner Name	
Attorney Docket Number	UF-368X

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ARROYO, HA et al. "A Syndrome of Hyperhidrosis, hypothermia, and bradycardia possibly due to central monoaminergic dysfunction," <i>Neurology</i> (March 1990), Volume 40 (3 Pt 1), pages 556-557.	
	R2	ARROYO, HA et al. "Episodic Spontaneous Hypothermia with Hyperhidrosis (Letters to the Editor)," <i>Pediatric Neurology</i> (1994), Volume 11, number 3, page 266.	
	R3	ASHTON, AK et al. "Cyproheptadine for drug-induced sweating (Letters to the Editor)," <i>American J. Psychiatry</i> (May 2002), Volume 159, number 5, pages 874-875.	
	R4	DAVIDSON, JR et al. "Hyperhidrosis in Social Anxiety Disorder," <i>Progress in Neuro-Psychopharmacology Biological Psychiatry</i> (December 2002), Volume 26, number 7-8, pages 1327-1331.	
	R5	SHETH, RD et al. "Episodic Spontaneous Hypothermia with Hyperhidrosis: Implication for Pathogenesis," <i>Pediatric Neurology</i> (1994), Volume 10, number 1, pages 58-60.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.